Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitalization | 14 | 2023 | 418 | 1.660 |
Why?
|
| South Africa | 49 | 2025 | 7596 | 1.620 |
Why?
|
| Humans | 60 | 2025 | 14537 | 1.500 |
Why?
|
| Tuberculosis | 4 | 2022 | 543 | 1.240 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2025 | 226 | 1.170 |
Why?
|
| HIV Infections | 6 | 2024 | 5097 | 0.960 |
Why?
|
| Hospital Mortality | 4 | 2023 | 95 | 0.940 |
Why?
|
| Politics | 1 | 2025 | 24 | 0.880 |
Why?
|
| Adult | 20 | 2024 | 5913 | 0.840 |
Why?
|
| Health Policy | 1 | 2025 | 140 | 0.810 |
Why?
|
| Pandemics | 9 | 2023 | 296 | 0.800 |
Why?
|
| Laboratory Infection | 1 | 2023 | 5 | 0.790 |
Why?
|
| Islam | 2 | 2021 | 5 | 0.740 |
Why?
|
| Hospitals | 6 | 2023 | 103 | 0.700 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 77 | 0.680 |
Why?
|
| Hypertension | 2 | 2022 | 419 | 0.680 |
Why?
|
| Middle Aged | 16 | 2024 | 3601 | 0.660 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 146 | 0.660 |
Why?
|
| Mortality | 1 | 2021 | 104 | 0.650 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 253 | 0.540 |
Why?
|
| Cohort Studies | 5 | 2024 | 967 | 0.540 |
Why?
|
| Public Health | 3 | 2023 | 124 | 0.510 |
Why?
|
| Female | 16 | 2024 | 9103 | 0.500 |
Why?
|
| Male | 15 | 2024 | 6754 | 0.490 |
Why?
|
| Prospective Studies | 4 | 2024 | 1160 | 0.480 |
Why?
|
| Risk Factors | 6 | 2023 | 1475 | 0.430 |
Why?
|
| Child | 14 | 2023 | 2242 | 0.400 |
Why?
|
| Rodent Control | 1 | 2013 | 2 | 0.390 |
Why?
|
| Rats | 1 | 2013 | 130 | 0.380 |
Why?
|
| Prevalence | 5 | 2024 | 1192 | 0.380 |
Why?
|
| Adolescent | 13 | 2023 | 2985 | 0.360 |
Why?
|
| Vaccines | 2 | 2023 | 86 | 0.350 |
Why?
|
| Disease Outbreaks | 2 | 2022 | 111 | 0.350 |
Why?
|
| Developing Countries | 2 | 2024 | 400 | 0.340 |
Why?
|
| Models, Econometric | 1 | 2011 | 3 | 0.340 |
Why?
|
| Total Quality Management | 1 | 2011 | 2 | 0.340 |
Why?
|
| Hospital Costs | 1 | 2011 | 4 | 0.340 |
Why?
|
| Mental Health Services | 1 | 2011 | 10 | 0.340 |
Why?
|
| Quality of Life | 2 | 2022 | 177 | 0.340 |
Why?
|
| Ethics, Business | 1 | 2009 | 1 | 0.310 |
Why?
|
| Congresses as Topic | 1 | 2009 | 20 | 0.310 |
Why?
|
| Marketing | 1 | 2009 | 6 | 0.310 |
Why?
|
| Commerce | 1 | 2009 | 22 | 0.300 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 0.290 |
Why?
|
| Aged | 6 | 2023 | 1740 | 0.290 |
Why?
|
| Mass Vaccination | 2 | 2022 | 11 | 0.280 |
Why?
|
| Seroepidemiologic Studies | 6 | 2023 | 109 | 0.270 |
Why?
|
| Hospitals, Public | 2 | 2022 | 45 | 0.270 |
Why?
|
| Young Adult | 9 | 2023 | 2498 | 0.250 |
Why?
|
| Comorbidity | 3 | 2022 | 188 | 0.250 |
Why?
|
| Global Health | 2 | 2024 | 193 | 0.240 |
Why?
|
| Bayes Theorem | 2 | 2023 | 81 | 0.240 |
Why?
|
| Retrospective Studies | 3 | 2023 | 799 | 0.230 |
Why?
|
| Policy Making | 1 | 2025 | 32 | 0.220 |
Why?
|
| Interviews as Topic | 1 | 2025 | 203 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 2 | 2021 | 551 | 0.210 |
Why?
|
| Immunization Programs | 3 | 2013 | 81 | 0.210 |
Why?
|
| Vulnerable Populations | 2 | 2022 | 30 | 0.210 |
Why?
|
| Laboratories | 2 | 2022 | 47 | 0.200 |
Why?
|
| Child, Preschool | 6 | 2023 | 1748 | 0.200 |
Why?
|
| Child Health Services | 2 | 2013 | 35 | 0.200 |
Why?
|
| Qualitative Research | 1 | 2025 | 321 | 0.190 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 284 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 17 | 0.190 |
Why?
|
| Fatigue | 1 | 2022 | 20 | 0.190 |
Why?
|
| Residential Facilities | 1 | 2022 | 3 | 0.190 |
Why?
|
| Poverty | 1 | 2023 | 152 | 0.190 |
Why?
|
| Quality of Health Care | 1 | 2022 | 62 | 0.190 |
Why?
|
| Long-Term Care | 1 | 2022 | 13 | 0.190 |
Why?
|
| Cognition Disorders | 1 | 2022 | 36 | 0.190 |
Why?
|
| Hepatitis D | 1 | 2022 | 4 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 62 | 0.180 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 370 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2021 | 35 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2022 | 56 | 0.170 |
Why?
|
| Epidemics | 1 | 2022 | 65 | 0.170 |
Why?
|
| Infant | 6 | 2023 | 2244 | 0.170 |
Why?
|
| Antitubercular Agents | 1 | 2023 | 322 | 0.170 |
Why?
|
| Homes for the Aged | 1 | 2020 | 2 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 239 | 0.160 |
Why?
|
| Obesity | 1 | 2022 | 367 | 0.150 |
Why?
|
| Incidence | 4 | 2023 | 685 | 0.140 |
Why?
|
| Health Resources | 2 | 2022 | 66 | 0.140 |
Why?
|
| Measles Vaccine | 3 | 2013 | 34 | 0.140 |
Why?
|
| Logistic Models | 2 | 2022 | 254 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 411 | 0.120 |
Why?
|
| Health Personnel | 3 | 2022 | 231 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 7 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 23 | 0.110 |
Why?
|
| Telemedicine | 1 | 2014 | 25 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 117 | 0.100 |
Why?
|
| National Health Programs | 1 | 2014 | 78 | 0.100 |
Why?
|
| Community Health Workers | 1 | 2014 | 66 | 0.100 |
Why?
|
| Oxygen | 2 | 2023 | 25 | 0.100 |
Why?
|
| Premature Birth | 1 | 2014 | 80 | 0.100 |
Why?
|
| Population Density | 1 | 2013 | 13 | 0.100 |
Why?
|
| Cities | 1 | 2013 | 37 | 0.100 |
Why?
|
| Cryptococcus | 1 | 2012 | 10 | 0.090 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 33 | 0.090 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2012 | 16 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 472 | 0.090 |
Why?
|
| Policy | 2 | 2022 | 42 | 0.090 |
Why?
|
| Immunization | 1 | 2012 | 63 | 0.090 |
Why?
|
| Measles | 1 | 2012 | 36 | 0.090 |
Why?
|
| Age Distribution | 2 | 2021 | 107 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 5 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2021 | 1479 | 0.090 |
Why?
|
| Mass Screening | 1 | 2012 | 245 | 0.080 |
Why?
|
| Infection Control | 2 | 2020 | 31 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 468 | 0.080 |
Why?
|
| Betacoronavirus | 2 | 2020 | 52 | 0.080 |
Why?
|
| Animals | 1 | 2013 | 1081 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 529 | 0.080 |
Why?
|
| South America | 1 | 2024 | 27 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 56 | 0.050 |
Why?
|
| Developed Countries | 1 | 2024 | 24 | 0.050 |
Why?
|
| Asia | 1 | 2024 | 72 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 47 | 0.050 |
Why?
|
| Reproduction | 1 | 2023 | 25 | 0.050 |
Why?
|
| Vitamin A | 2 | 2013 | 10 | 0.050 |
Why?
|
| Africa | 1 | 2024 | 376 | 0.050 |
Why?
|
| Poliovirus Vaccines | 2 | 2013 | 11 | 0.050 |
Why?
|
| Vitamins | 2 | 2013 | 23 | 0.050 |
Why?
|
| Private Sector | 1 | 2023 | 45 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2022 | 3 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 19 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 163 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.050 |
Why?
|
| Internationality | 1 | 2022 | 36 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2023 | 66 | 0.050 |
Why?
|
| Pain | 1 | 2022 | 41 | 0.050 |
Why?
|
| Rifampin | 1 | 2023 | 197 | 0.050 |
Why?
|
| Government | 1 | 2022 | 13 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 18 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2022 | 52 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 149 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2022 | 64 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 133 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 253 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 89 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 171 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 365 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 101 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 260 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 507 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 2021 | 115 | 0.040 |
Why?
|
| Assisted Living Facilities | 1 | 2020 | 1 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2020 | 3 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 39 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 231 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 82 | 0.040 |
Why?
|
| Patient Care | 1 | 2020 | 10 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 106 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 227 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 280 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 179 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 370 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 654 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1422 | 0.030 |
Why?
|
| Zambia | 1 | 2014 | 115 | 0.030 |
Why?
|
| Vitamin A Deficiency | 1 | 2013 | 5 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2013 | 30 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 83 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 133 | 0.020 |
Why?
|
| Helminthiasis | 1 | 2013 | 7 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2013 | 9 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 96 | 0.020 |
Why?
|
| Health Promotion | 1 | 2013 | 109 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2013 | 167 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2013 | 240 | 0.020 |
Why?
|
| Pregnancy | 1 | 2014 | 1862 | 0.020 |
Why?
|